Activate Immunotherapy
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Activate Immunotherapy
Leqembi’s EU Approval Process Delayed Over Advisory Group COI Considerations
The EU regulatory agency’s discussions for lecanemab’s approval are hit by a decision to annul advice from an advisory committee due to the implications of a Court of Justice ruling on the handling of experts' competing interests.
Bayer’s New Pharma Leader To Spearhead Growth From US
The troubled conglomerate is accelerating its moves to streamline its business, with the creation of a more customer- and US-focused pharma division.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
AstraZeneca Spends $800m On Amolyt And Awaits A Readout
The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- NovaRx Corporation
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice